Plain-English translation of NCT07022535 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a personalized approach to treating advanced ovarian cancer, fallopian tube cancer, or peritoneal cancer. Instead of using a standard surgery schedule for everyone, doctors will use a specific blood test called a CA-125 elimination rate to decide whether you're ready for surgery sooner or if you need more chemotherapy first. This aims to give each patient the best timing for their individual situation.
Currently, doctors use a one-size-fits-all approach to timing surgery in advanced ovarian cancer. This study exists to see if using a blood marker to measure how your body responds to chemotherapy can help doctors make better, more personalized decisions about when you're ready for surgery—potentially improving your outcomes.
You likely qualify if…
You likely don't qualify if…
You will receive chemotherapy as planned, and the study will measure your CA-125 blood levels at specific weeks (week 4 and week 5 after your first chemotherapy cycle). Based on your results, your doctor will either proceed to surgery or recommend additional chemotherapy before surgery. You will also have imaging scans to assess whether surgery is possible. Throughout the study, you'll continue with additional chemotherapy after surgery if needed, with regular follow-up visits to monitor your response.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Hong Kong